Netflix, DocuSign And A Health Care Stock On CNBC’s ‘Final Trades’

On CNBC's 'Halftime Report Final Trades', Stephen Weiss recommended Netflix (NASDAQ:NFLX), which has an Overweight rating from Morgan Stanley, although the price target was lowered from $83 to $80. Jim Lebenthal endorsed AbbVie (NYSE:ABBV), noting strong momentum following the FDA's granting of two Breakthrough Therapy Designations for a new treatment. Jenny Van Leeuwen Harrington highlighted DocuSign (NASDAQ:DOCU), which reported second-quarter revenue of $875.75 million, exceeding estimates, and has a free cash flow yield of nearly 10%. On October 9, Netflix shares rose 0.4% to $70.61, AbbVie increased 1.7% to $281.12, while DocuSign's shares fell 0.2% to $70.97.